Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SMMT Summit Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: SMMT
Price (delayed)
$19.56
Market cap
$14.53B
P/E Ratio
N/A
Dividend/share
N/A
EPS
$0
Enterprise value
$14.32B
Summit Therapeutics, empowered by its Discuva Platform, the Company's innovative antibiotic discovery engine, led by Dr. Ventzislav Stefanov and supported by BARDA and Carb-X funding, intends to be the leader
Highlights
The debt has dropped by 94% year-on-year and by 11% since the previous quarter
SMMT's quick ratio has soared by 55% YoY and by 4.9% QoQ
The net income has plunged by 108% YoY and by 9% from the previous quarter
SMMT's equity is down by 11% since the previous quarter
Key stats
What are the main financial stats of SMMT
Market
Valuations
Earnings
Shares outstanding
742.67M
Market cap
$14.53B
Enterprise value
$14.32B
Price to earnings (P/E)
N/A
Price to book (P/B)
41.9
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$250.46M
Net income
-$240.76M
EBIT
-$232.07M
EBITDA
-$231.98M
Free cash flow
-$173.7M
Per share
Balance sheet
Liquidity
EPS
$0
EPS diluted
$0
Free cash flow per share
-$0.24
Book value per share
$0.47
Revenue per share
$0
TBVPS
$0.52
Total assets
$383.82M
Total liabilities
$39.49M
Debt
$6.45M
Equity
$344.33M
Working capital
$335.87M
Debt to equity
0.02
Current ratio
10.63
Quick ratio
10.37
Net debt/EBITDA
0.89
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-57.9%
Return on equity
-70.5%
Return on invested capital
-84.7%
Return on capital employed
-66.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SMMT stock price
How has the Summit Therapeutics stock price performed over time
Intraday
-5.14%
1 week
-24.88%
1 month
-29.89%
1 year
167.58%
YTD
9.61%
QTD
1.4%
Financial performance
How have Summit Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$250.46M
Net income
-$240.76M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 118% YoY and by 11% from the previous quarter
The net income has plunged by 108% YoY and by 9% from the previous quarter
Price vs fundamentals
How does SMMT's price correlate with its fundamentals
Growth
What is Summit Therapeutics's growth rate over time
Valuation
What is Summit Therapeutics stock price valuation
P/E
N/A
P/B
41.9
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The P/B is 169% above the 5-year quarterly average of 16.4 and 27% above the last 4 quarters average of 34.9
SMMT's equity is down by 11% since the previous quarter
Efficiency
How efficient is Summit Therapeutics business performance
SMMT's return on invested capital has dropped by 95% year-on-year and by 15% since the previous quarter
The company's return on equity rose by 48% YoY and by 15% QoQ
The ROA has grown by 4.8% from the previous quarter but it has contracted by 4.3% YoY
Dividends
What is SMMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SMMT.
Financial health
How did Summit Therapeutics financials performed over time
SMMT's total assets has soared by 117% YoY but it is down by 12% from the previous quarter
The total liabilities has dropped by 70% year-on-year and by 16% since the previous quarter
The debt is 98% smaller than the equity
Summit Therapeutics's debt to equity has plunged by 99% YoY
The debt has dropped by 94% year-on-year and by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.